Japan approves GSK’s Sotrovimab COVID-19 antibody treatment

This post was originally published on this site

https://i-invdn-com.investing.com/trkd-images/LYNXMPEH8Q0KR_L.jpg

TOKYO (Reuters) – Japan has approved GlaxoSmithKline (NYSE:GSK) and Vir Biotechnology (NASDAQ:VIR)’s Sotrovimab as an antibody treatment for coronavirus, Health Minister Norihisa Tamura said on Monday.

The antibody treatment is for mild to moderate COVID-19 cases which do not require oxygen supplementation, GSK said when it applied for fast-track approval this month.

Add Comment